Financial services firm Motilal Oswal has officially initiated coverage on Aster DM Healthcare, assigning a 'Buy' rating to the stock. With a price target set at Rs 910, the brokerage firm is signaling strong confidence in the healthcare provider's long-term trajectory.
Analysts highlight several key drivers behind this optimistic outlook, including significant operational synergies following recent structural mergers and an aggressive capacity expansion strategy. These moves are expected to bolster the firm’s competitive positioning in the domestic healthcare market.
The research report outlines a promising financial outlook for the coming years, forecasting strong double-digit growth metrics:
- Revenue growth at a CAGR of 19.5%
- EBITDA growth at a CAGR of 25%
- Net profit (PAT) expansion at a CAGR of 33%
By the conclusion of FY28, the brokerage anticipates that improved operating efficiencies and higher bed occupancy levels will significantly enhance the company's bottom line, rewarding patient investors.
